304 related articles for article (PubMed ID: 2312719)
1. Effects of a cholecystokinin receptor antagonist on intestinal phase of pancreatic and biliary responses in man.
Hildebrand P; Beglinger C; Gyr K; Jansen JB; Rovati LC; Zuercher M; Lamers CB; Setnikar I; Stalder GA
J Clin Invest; 1990 Mar; 85(3):640-6. PubMed ID: 2312719
[TBL] [Abstract][Full Text] [Related]
2. Effect of a cholecystokinin antagonist on meal-stimulated insulin and pancreatic polypeptide release in humans.
Hildebrand P; Ensinck JW; Ketterer S; Delco F; Mossi S; Bangerter U; Beglinger C
J Clin Endocrinol Metab; 1991 May; 72(5):1123-9. PubMed ID: 2022712
[TBL] [Abstract][Full Text] [Related]
3. Effects of loxiglumide on pancreatic exocrine secretion stimulated by meal in conscious dogs.
Ninomiya K; Saito T; Wakatsuki K; Saeki M; Kato T; Edano K; Kasai H; Kimura K; Fujii M
Arzneimittelforschung; 1998 Jan; 48(1):55-7. PubMed ID: 9522033
[TBL] [Abstract][Full Text] [Related]
4. Comparison of loxiglumide, a cholecystokinin receptor antagonist, and atropine on hormonal and meal-stimulated pancreatic secretion in man.
Gabryelewicz A; Kulesza E; Konturek SJ
Scand J Gastroenterol; 1990 Jul; 25(7):731-8. PubMed ID: 2396088
[TBL] [Abstract][Full Text] [Related]
5. Effects of loxiglumide on pancreatic exocrine secretion stimulated by cholecystokinin-8 in conscious dogs.
Ninomiya K; Saito T; Wakatsuki K; Saeki M; Kato T; Kasai H; Kimura K; Fujii M
Arzneimittelforschung; 1998 Jan; 48(1):52-4. PubMed ID: 9522032
[TBL] [Abstract][Full Text] [Related]
6. Proglumide inhibits cholecystokinin and meal-stimulated pancreatic secretion and release of pancreatic polypeptide.
Beauchamp RD; Gomez G; Nealon WH; Townsend CM; Greeley GH; Thompson JC
Surgery; 1990 Sep; 108(3):553-8. PubMed ID: 2396199
[TBL] [Abstract][Full Text] [Related]
7. Cholecystokinin receptor antagonist loxiglumide: influence on bilio-pancreatic secretion and gastrointestinal hormones in man.
Schmidt WE; Creutzfeldt W; Höcker M; Choudhury AR; Nustede R; Schleser A; Nitsche R; Rovati LC; Schafmayer A; Fölsch UR
Digestion; 1990; 46 Suppl 2():232-9. PubMed ID: 2262057
[TBL] [Abstract][Full Text] [Related]
8. Inhibitory effect of intraduodenal infusion of loxiglumide on pancreatic exocrine secretion.
Tanikawa M; Hayakawa T; Kondo T; Shibata T; Kitagawa M; Kodaira T; Hamaoka T
Arzneimittelforschung; 1993 Jan; 43(1):35-9. PubMed ID: 8447844
[TBL] [Abstract][Full Text] [Related]
9. Physiological control of cholecystokinin release and pancreatic enzyme secretion by intraduodenal bile acids.
Koop I; Schindler M; Bosshammer A; Scheibner J; Stange E; Koop H
Gut; 1996 Nov; 39(5):661-7. PubMed ID: 9026479
[TBL] [Abstract][Full Text] [Related]
10. Role of cholecystokinin in the regulation of gastric emptying and pancreatic enzyme secretion in humans. Studies with the cholecystokinin-receptor antagonist loxiglumide.
Fried M; Erlacher U; Schwizer W; Löchner C; Koerfer J; Beglinger C; Jansen JB; Lamers CB; Harder F; Bischof-Delaloye A
Gastroenterology; 1991 Aug; 101(2):503-11. PubMed ID: 2065926
[TBL] [Abstract][Full Text] [Related]
11. Role of CCK in regulation of pancreaticobiliary functions and GI motility in humans: effects of loxiglumide.
Schmidt WE; Creutzfeldt W; Schleser A; Choudhury AR; Nustede R; Höcker M; Nitsche R; Sostmann H; Rovati LC; Fölsch UR
Am J Physiol; 1991 Feb; 260(2 Pt 1):G197-206. PubMed ID: 1996640
[TBL] [Abstract][Full Text] [Related]
12. Cholecystokinin in the control of gastric acid and plasma gastrin and somatostatin secretion in healthy subjects and duodenal ulcer patients before and after eradication of Helicobacter pylori.
Konturek JW
J Physiol Pharmacol; 1994 Dec; 45(4 Suppl 1):3-66. PubMed ID: 7787215
[TBL] [Abstract][Full Text] [Related]
13. Effects of cholecystokinin-receptor blockade on pancreatic and biliary function in healthy volunteers.
Schwarzendrube J; Niederau M; Lüthen R; Niederau C
Gastroenterology; 1991 Jun; 100(6):1683-90. PubMed ID: 2019374
[TBL] [Abstract][Full Text] [Related]
14. Loxiglumide. A new proglumide analog with potent cholecystokinin antagonistic activity in the rat pancreas.
Otsuki M; Fujii M; Nakamura T; Okabayashi Y; Tani S; Fujisawa T; Koide M; Baba S
Dig Dis Sci; 1989 Jun; 34(6):857-64. PubMed ID: 2470557
[TBL] [Abstract][Full Text] [Related]
15. Roles of endogenous cholecystokinin in biliary, pancreatic and gastric function: studies with L-364,718, a specific cholecystokinin receptor antagonist.
Pendleton RG; Bendesky RJ; Schaffer L; Nolan TE; Gould RJ; Clineschmidt BV
J Pharmacol Exp Ther; 1987 Apr; 241(1):110-6. PubMed ID: 2437283
[TBL] [Abstract][Full Text] [Related]
16. Effects of cholecystokinin receptor blockade on circulating concentrations of glucose, insulin, C-peptide, and pancreatic polypeptide after various meals in healthy human volunteers.
Niederau C; Schwarzendrube J; Lüthen R; Niederau M; Strohmeyer G; Rovati L
Pancreas; 1992; 7(1):1-10. PubMed ID: 1557335
[TBL] [Abstract][Full Text] [Related]
17. Effect of the specific cholecystokinin-receptor antagonist loxiglumide on bombesin stimulated pancreatic enzyme secretion in man.
Jebbink MC; Jansen JB; Mooy DM; Rovati LC; Lamers CB
Regul Pept; 1991 Feb; 32(3):361-8. PubMed ID: 1714084
[TBL] [Abstract][Full Text] [Related]
18. Effect of cholecystokinin receptor antagonist on pancreatic responses to exogenous gastrin and cholecystokinin and to meal stimuli.
Konturek SJ; Tasler J; Cieszkowski M; Szewczyk K; Hladij M
Gastroenterology; 1988 Apr; 94(4):1014-23. PubMed ID: 3345871
[TBL] [Abstract][Full Text] [Related]
19. Role of endogenously released cholecystokinin in determining postprandial insulin levels in man: effects of loxiglumide, a specific cholecystokinin receptor antagonist.
Baum F; Nauck MA; Ebert R; Cantor P; Hoffmann G; Choudhury AR; Schmidt WE; Creutzfeldt W
Digestion; 1992; 53(3-4):189-99. PubMed ID: 1291406
[TBL] [Abstract][Full Text] [Related]
20. Cholecystokinin receptor antagonist loxiglumide modulates plasma levels of gastro-entero-pancreatic hormones in man. Feedback control of cholecystokinin and gastrin secretion.
Schmidt WE; Creutzfeldt W; Höcker M; Nustede R; Choudhury AR; Schleser A; Rovati LC; Fölsch UR
Eur J Clin Invest; 1991 Oct; 21(5):501-11. PubMed ID: 1752290
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
